Biodexa Pharmaceuticals Announces A Ratio Change On Its ADRs From 1 ADS Representing 400 Ordinary Shares, To The New Ratio Of 1 ADR Representing 10,000 Ordinary Shares (1-For-25) ; Effective Date Of The Ratio Change Is Expected To Be October 4,2024.
Biodexa Pharmaceuticals Announces A Ratio Change On Its ADRs From 1 ADS Representing 400 Ordinary Shares, To The New Ratio Of 1 ADR Representing 10,000 Ordinary Shares (1-For-25) ; Effective Date Of The Ratio Change Is Expected To Be October 4,2024.
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing four hundred (400) ordinary shares, to the new ratio of one (1) ADR representing ten thousand (10,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be October 4,2024.
Biodexa Pharmaceuticals PLC（纳斯达克：BDRX）是一家以收购为重点的临床阶段生物制药公司，致力于为治疗未满足医疗需求的疾病开发创新产品。今天，宣布美国存托凭证（"ADR"）的比例变化，从每一份ADR代表四百（400）股普通股变更为每一份ADR代表一万（10,000）股普通股（"比例变化"）。比例变化的生效日期预计为2024年10月4日。
Pursuant to the Ratio Change, ADR holders will be required on a mandatory basis to surrender their ADRs for cancellation and exchange to receive one (1) new ADR (New CUSIP: 59564R807) for every twenty-five (25) old ADRs (Old CUSIP: 59564R708). No fractional ADRs will be allocated. The aggregate fractions, if any, will be sold and the net proceeds will be distributed to the entitled ADR holder. The Company's Depositary, JP Morgan Chase Bank, N.A. will contact ADR holders and arrange for the exchange of their existing ADRs for new ADRs.
根据比例变化，ADR持有人将被要求强制性地交出其ADR以换取每二十五（25）个旧ADR（旧CUSIP：59564R708）换取一（1）个新ADR（新CUSIP：59564R807）。不会分配任何零数ADR。如果有任何零数ADR，将会出售并将净收益分配给有权ADR持有人。公司的托管银行摩根大通银行会联系ADR持有人，并安排交换其现有ADR为新的ADR。
